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SUMMARY.
Most types of metastatic solid tumors cannot be cured by the available chemotherapeu-
tic agents. Although this failure is often a result of intrinsic or acquired drug resistance,
ineffective drug dosage or scheduling may contribute to treaffnent inefficacy. The thera-
peutic index of drugs may be improved by modifying the delivery schedule, such as ex-
panding the infusion time, in order to increase the exposure of metabolically active tu-
mor cells to the drug and simultaneously decrease toxicicty by avoiding high peaklevels
of the drug. The recent development of reliable portable pumps suirable for continuous
drug administration, and safe long-term venous access catheters has made the infusion
of cytostatic agents feasible over periods of several weeks.
In chapter 1 a review is given of continuous infusion regimens with doxorubicin
(adriamycin), and our own studies with continuous infusion of epirubicin and mitoxan-
trone.
In chapter 2 adnanycin and mitoxantrone accumulation are studied in a human
small cell lung carcinoma cell line and in the adriamycin resistant subline lacking cross
resistance to mitoxanrone. An energy dependent efflux puÍnp is present for adriamycin
in the resistant cell line. No pleiotropic drug resistant genotype and phenotype could be
detected in this cell line. An energy dependent efflux pump can be present in resistant
cells without the pleioropic drug resistance genotype, and can lead to lower cellular
drug concentrations. l,ower cellular drug concentrations do not necessarily lead to less
cytotoxicity, as seen for mitoxantrone in ttris study. Resistance to adriamycin should not
rule out the use of mitoxanrone, especially in cases not showing pleitropic drug resi-
stance characteristics.
In chapter 3 a phase I and pharmacokinetic study with 21 days continuous infusion
of epirubicin is described. A dose of 6 mg/mzlday for 3 weeks was found to be the opti-
mal dose for evaluation of antitumor efficacy in phase II studies. Pharmacokinetic stu-
dies were performed by high performance liquid chromatography with fluorometric de-
tection. Plasma steady state was reached after 57 hours of infusion. During steady state
there was a linear relationship between epirubicin dose administered and epirubicin le-
vel in plasma, and in leucocytes. The area under the curve in leucocytes was higher with
continuous infusion of 6 mg/mzlday for 2l days compared with an equal myelotoxic
dose of 80 mg/mz administered as bolus injection. This method of continuous infusion
of epirubicin may be a way to increase innacellular drug uptake as expressed by intra-
cellular area under the curve.
In chapter 4 a phase II stmdy with conrinuous infusion of epirubicin in a dose of
6 mglmzlday during 21 days repeated every six weeks in patients with advanced meta-
static colorectal cancer is described. Fourteen patients were treated with a total of 32 cy-
cles. There were no complete or partial remissions. Stable disease was observed in ele-
ven patients, with a median duration of 12 weeks. Compared to phase II studies with
bolus injection of epirubicin every 3 weeks, less myelotoxicity was seen with continu-
ous infusion. We conclude that epirubicin given in a continuous infusion schedule is
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well lolerated and causes minimal toxicity, but cannot be recommended for the treat-
ment of patients with metastatic colorectal cancer.
In chapter 5 an update of the preliminary results of a phase II study with continuous
infusion of epirubicin in patients with advanced gastric cancer is given. A dose of 6 mg/
mzlday during 2l days was administerd and courses rffere repeated every six weeks. In
18 evaluable patients who received a total of 43 courses two complete responses and
one partial response were observed. One patient had a minor response and 10 patients
had stable disease with a median duration of 12 weeks. Treatment was very well tolera-
ted and toxicity was limited. Two patients developed a subclavian vein thrombosis due
to the totally implantable catheter. We conclude that continuous infusion of epirubicin
might be an interesting treatÍnent schedule in patients with advanced gastric cancer.
Final assessment of the remission rate must await additional patient data.
In chapter 6 a phase I and pharmacokinetic study with 2l days continuous infusion
of mitoxantÍone, an anthracenedione with structural similarities to doxorubicin (adria-
mycin), is described. The maximum tolerated dose for a 2l day continuous infusion
schedule was determined in this study, and pharmacokinetic studies were performed in
plasma and leukocytes. A maximal tolerated dose of l.l mg/mzlf,2y for 2l days conti-
nuous infusion was found and recommended for evaluation of antitumor efficacy in
phase II studies. Similar to continuous infusion with epirubicin a linear relationship was
found between mitoxantrone dose administered and mitoxanEone level in plasma.
Steady state in plasma was reached after 35 hours. Mitoxantrone level in leukocytes did
still increase significantly during the infusion period, and did not reach steady state. The
area under the curve in leukocytes was higher with continuous infusion of 1.1
mglmzl6z, for 2l days compared to a bolus injection of 12 mglmz. Mitoxantrone could
be detected in plasma for at least 5 days after the end of the infusion and in leukocytes
for at least 14 days after the end of the infusion. Like continuous infusion with epirubi-
cin, continuous infusion of mitoxantrone may be a way to increase intracellular drug up-
take as expressed by the inracellulaÍ area under the curve.
In chapter 7 an evaluation of a totally implanted venous access port and portable
pump in a continuous infusion chemotherapy schedule on an outpatient basis in the first
50 patients is given. The complication rate was low. Subclavian vein thrombosis was
seen in one patient, and one patient developed pulmonary embolism. Needle dislocation
was observed in two patients. No septicemia was seen. Pump functioning was efficient
and mechanical malfunction did not occur. V/e conclude that a totally implanted venous
access port and portable pump are a safe and reliable route of adminstration for cytosta-
tic drugs on an outpatient basis.
In chapter 8 the patient education progÍam for a continuous infusion regimen on an
outpatient basis is described. The policies and procedures for the use of the pump, the
mixing of the cytostatic drug, and an educational program for pacients and their relatives
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CONCLUSION.
This thesis describes some clinical and pharmacokinetic studies with continuous infusi-
on of doxorubicin, epirubicin and mitoxantrone. Continuous infusion has advantages
compared to bolus injection therapy. Toxicity, especially myelotoxicity, nausea and vo-
miting, is decreased with continuous infusion, although the use of a totally implantable
venous access port and a portable pump for continuous drug administration may lead to
additional complications. Due to the phase I and II character of the studies it is difficult
to draw definite conclusions on the efficacy of continuous infusion of doxorubicin, epi-
rubicin and mitoxantrone. Pharmacokinetic studies do show a significant increase in in-
tracellular drug uptake as expressed by intracellular area under the curve with continu-
ous infusion, compared to ttre intracellular drug uptake after an equimyelotoxic bolus
injection. This might lead to a higher tumor response rate with continuous infusion.
Further well-controlled comparitive trials are necessary to investigate the role of conti-
nuous infusion therapy in cancer treatment. For the patients continuous infusion of cyto-
static agents on an outpatient basis is a more attractive treatment schedule compared to a
bolus infusion schedule, for which admission to a hospital is often required and which
mostly leads to more severe toxicity. In our studies with continuous infusion patients
were generally very positive in their reaction on how they experienced treatment with
continuous infusion. The fact that they were self-supporting and responsible for their
own treatment was a positive experience for most patients and their relatives. In further
studies with continuous infusion of cytostatic agents it will be interesting to perform an
objective quality of life study in these patients.
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